Oncology Business Management | Specialty

Reimbusement and Managed Care News

June 10th 2010

Clinical Abstracts From Overseas: June 10, 2010

June 10th 2010

OncLive News Briefs: June 9, 2010

June 9th 2010

ASCO Policy Change Creates Massive Avalanche of Pre-Meeting Data

June 9th 2010

When ASCO decision-makers decided to revise the manner in which they disseminate eagerly anticipated clinical research data, the news made headlines and reverberations that were felt throughout the worlds of oncology research, practice, finance, and investment.

The American Association for Cancer Research Annual Meeting

June 9th 2010

The American Association for Cancer Research (AACR), Philadelphia, is considered the world�s oldest and largest oncology-related scientific organization. Currently celebrating its centennial, the AACR recently held its 100th annual meeting at the San Diego Convention Center from April 12�16, 2008. The following sections provide a general overview of breaking news and session highlights from the conference.

Practical Information for the Community-Based Oncologist

June 9th 2010

This issue's cover story focuses on the 100th annual meeting of the American Association of Cancer Research held April 12-16 in San Diego,providing a general overview of breaking new and session highlights.

The Academy: June 9, 2010

June 9th 2010

Academic research is fueling tremendous strides in oncology and biotechnology. The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

Physicians Financial News: June 8, 2010

June 8th 2010

Pegfilgrastim for Reducing Incidence of Infection by Febrile Neutropenia

June 8th 2010

New research presented at ASCO highlights advantages of pegfilgrastim in patients receiving chemotherapy for a wide variety of solid tumors and hematologic malignancies.

The Management of Oral Mucositis in Oncology

June 8th 2010

Oral mucositis is a costly consequence of cancer therapy that can impede the efficacy of anticancer therapy. Simple preventive measures can greatly improve the patient�s outcome and quality of life.

Clinical Trial Reports: June 7, 2010

June 7th 2010

Reimbursement and Managed Care News: June 7, 2010

June 7th 2010

Clinical Abstracts From Overseas: June 7, 2010

June 7th 2010

New Angiogenesis Inhibitor May Be Effective Against a Broad Range of Cancers

June 7th 2010

Researchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.

Managing Hypertension Associated With VEGF Inhibitors

June 3rd 2010

Patients with cancer whose treatment includes any drug that inhibits signaling via the vascular endothelial growth factor (VEGF) pathway should receive regular blood pressure (BP) monitoring according to a panel of experts convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.

West's Points: Evolving Issues With ALK Rearrangements

June 3rd 2010

H. Jack West, MD, takes a moment to talk about what he is finding in regard to anaplastic lymphoma kinase (ALK) rearrangements seen in approximately 4% of patients with non�small cell lung cancer, as reviewed by Shaw et al in a September 2009 issue of the Journal of Clinical Oncology.

OncLive News Briefs: June 10, 2010

June 3rd 2010

We summarize the latest oncology news.

Memorial Sloan-Kettering Cancer Center: A Venerable Institution That Shows No Signs of Slowing Down

June 3rd 2010

Founded in 1884, the New York City institute known today as Memorial Sloan-Kettering Cancer Center (MSKCC) is the world's oldest and largest private cancer center.

Poniard Pharmaceuticals Reports First Quarter Financials, Picoplatin Update

June 3rd 2010

Merck, ARIAD Restructure Ridaforolimus Collaboration

June 3rd 2010

Merck and ARIAD Pharmaceuticals have announced the restructuring of their collaboration on the effort to bring ridaforolimus�ARIAD�s investigational mTOR inhibitor�to market. The companies, which first entered into the collaboration almost 3 years ago, have been working together to develop the agent in multiple potential cancer indications.